Article Text

Download PDFPDF
PKP-009 Markers of cardiovascular risk and age-related macular degeneration
  1. N Manresa-Ramón1,
  2. J Mulero2,
  3. P Zafrilla2,
  4. M Losada3,
  5. P Selvi-Sabater1,
  6. I Sánchez-Martinez1,
  7. I Sánchez-Mulero1,
  8. MC Sánchez-Mulero1,
  9. B Arribas-Díaz1
  1. 1Hospital Morales Meseguer, Pharmacy, Murcia, Spain
  2. 2Catholic University of San Antonio, Department of Food Technology and Nutrition., Murcia, Spain
  3. 3Hospital Morales Meseguer, Ophtalmology, Murcia, Spain


Background Many authors have hypothesised that cardiovascular disorders and age-related macular degeneration (AMD) share common antecedents and suggested that novel biomarkers associated with CVD be evaluated for their potential relationship with AMD.

Purpose To analyse the effect of anti-VEGF treatment on homocysteine levels and CRP (C-Reactive Protein) levels in patients with AMD.

Materials and methods A total of 43 patients with exudative AMD and with no previous anti-VEGF treatment were treated with two anti-VEGF treatments: ranibizumab and pegaptanib sodium. The follow up was 6 months. The homocysteine (HCY) and CRP levels were determined before and after treatment.

HCY levels were measured quantitatively using an intensifying immunonephelometric particle test in a BN ProSpec analyzer (Tiez, 1995) and CRP analysis was performed by an immunoturbidimetric test (Eda et al. 1998).

Results Mean plasma homocysteine level at baseline was 13.1 ± 4.2 mmol/L in patients treated with pegaptanib and at 6 months these values had not changed. In the same way the patients treated with ranibizumab showed no changes in mean baseline plasma homocysteine (12.8 ± 2.5 mmol/L) after intravitreal treatment with ranibizumab. The mean homocysteine values were within the normal range, between 5–20 mmol/L.

Of all patients analysed, only 3 of them initially had CRP levels above normal (5–10 mg /L). After antiangiogenic treatment with both ranibizumab and pegaptanib there was a significant increase in CRP. In patients with normal values, anti-angiogenic treatment produced no significant changes.

Conclusions We did not find any results in our study to suggest that anti-VEGF treatment in patients with AMD increases cardiovascular risk predictors.

No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.